Giselle J Moore-Higgs, APRN, PhD
Clinical Programs, Asst Dir 4
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0003-1609-0701
Publications
2023
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders.
Pediatric blood & cancer.
70(7)
[DOI] 10.1002/pbc.30322.
[PMID] 37046407.
2008
Is there a role for routine use of MRI in selection of patients for breast-conserving cancer therapy?
Journal of the American College of Surgeons.
206(5):1045-50; discussion 1050
[DOI] 10.1016/j.jamcollsurg.2007.12.039.
[PMID] 18471753.
2006
Radiation options for early stage breast cancer.
Seminars in oncology nursing.
22(4):233-41
[PMID] 17095399.
2003
The role of licensed nursing personnel in radiation oncology part a: results of a descriptive study.
Oncology nursing forum.
30(1):51-8
[PMID] 12515983.
2003
The role of licensed nursing personnel in radiation oncology part B: integrating the ambulatory care nursing conceptual framework.
Oncology nursing forum.
30(1):59-64
[PMID] 12515984.
2002
Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both.
Cancer.
94(11):2967-80
[PMID] 12115386.
2000
Is radiation therapy a preferred alternative to surgery for squamous cell carcinoma of the base of tongue?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
18(1):35-42
[PMID] 10623691.
1999
Description of the role of nonphysician practitioners in radiation oncology.
International journal of radiation oncology, biology, physics.
45(1):163-9
[PMID] 10477020.
1999
Non-physician practitioners in radiation oncology: advanced practice nurses and physician assistants.
International journal of radiation oncology, biology, physics.
45(2):255-63
[PMID] 10487543.
1999
The optimal dose of radiation in Hodgkin’s disease: an analysis of clinical and treatment factors affecting in-field disease control.
International journal of radiation oncology, biology, physics.
44(3):551-61
[PMID] 10348284.
Grants
Nov 2019
– Jun 2023
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Role: Other
Funding: H LEE MOFFITT CANCER CTR & RES INST
via FL DEPT OF HLTH
Oct 2019
ACTIVE
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)
Role: Project Manager
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2019
ACTIVE
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)
Role: Project Manager
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2018
– Aug 2021
A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Role: Other
Funding: PHARMACEUTICAL RES ASSO
via GENENTECH INC
Mar 2018
– Jan 2022
Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice
Role: Other
Funding: Octapharma USA
Contact Details
Phones:
- Business:
- (352) 273-9050
Emails:
- Business:
- mooregj@ufl.edu
Addresses:
- Business Mailing:
-
1600 SW ARCHER ROAD, HD-204
1600 SW ARCHER RD # HD-204
PEDIATRIC HEMATOLOGY ONCOLOGY
GAINESVILLE FL 32610 - Business Street:
-
DEPARTMENT OF PEDIATRIC HEMATOLOGY ONCOLOGY
1600 SW ARCHER RD RM MSB-351
GAINESVILLE FL 32610